Regeneron Pharmaceuticals, Intellia Therapeutics Have Expanded Research Collaboration To Develop Additional In Vivo CRISPR-based Gene Editing Therapies Focused On Neurological And Muscular Diseases
Portfolio Pulse from Benzinga Newsdesk
Regeneron Pharmaceuticals and Intellia Therapeutics have expanded their research collaboration to develop additional in vivo CRISPR-based gene editing therapies for neurological and muscular diseases. The companies will research two in vivo non-liver targets, with Intellia leading the design of the editing methodology and Regeneron leading the design of the targeted viral vector delivery approach. Each company will have the opportunity to lead potential development and commercialization of product candidates for one target.
October 03, 2023 | 11:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Intellia Therapeutics has expanded its research collaboration with Regeneron Pharmaceuticals to develop additional CRISPR-based gene editing therapies. Intellia will lead the design of the editing methodology.
The expanded collaboration with Regeneron Pharmaceuticals allows Intellia to further its research and development in gene editing therapies. This could potentially lead to new product candidates, which could have a positive impact on the company's future revenues and stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Regeneron Pharmaceuticals has expanded its research collaboration with Intellia Therapeutics to develop additional CRISPR-based gene editing therapies. Regeneron will lead the design of the targeted viral vector delivery approach.
The expanded collaboration with Intellia Therapeutics allows Regeneron to further its research and development in gene editing therapies. This could potentially lead to new product candidates, which could have a positive impact on the company's future revenues and stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100